Compare Harmony Gold Mining Co. (HMY) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Harmony Gold Mining Co. vs Vertex Pharmaceuticals Incorporated — how do they compare? Harmony Gold Mining Co. trades at $16.88 (market cap $10.02B), while Vertex Pharmaceuticals Incorporated trades at $510.08 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 12.7× Harmony Gold Mining Co.'s market cap, and Harmony Gold Mining Co. pays a 4.63% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Harmony Gold Mining Co. for 45 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| HMY | VRTX | |
|---|---|---|
Market Cap | $10.02B | $127.55B |
Volume | 3,643,683 | 1,487,944 |
Sector | Basic Materials | Health |
52-Week High | $26.04 | $557.96 |
52-Week Low | $13.32 | $407.37 |
Typical Hold Time | 45 Days | 120 Days |
Enterprise Value | $10.07B | $121.68B |
Dividend Yield | 4.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Harmony Gold Mining (HMY) trades at $16.84, up 2.12% today, showing strong profitability with 29.57% net margins and robust cash flow generation. The stock appears fundamentally undervalued with a P/E of 6.02 and EV/EBITDA of 3.54, though technical indicators signal bearish momentum with the price near key support levels. Recent earnings showed mixed results with two beats and two misses, while the company continues its strategic transition toward copper production diversification.
HMY presents a compelling value opportunity given its attractive valuation multiples and strong operational performance, but faces near-term technical headwinds and execution risks in its copper expansion strategy. The bearish technical setup and cautious analyst consensus (70% hold rating) suggest patience may be warranted despite the company's solid fundamentals and record fiscal 2026 results.
Vertex Pharmaceuticals (VRTX) trades at $503.25, down 0.47% on the day, with a bearish technical signal despite strong fundamentals. The company maintains dominant cystic fibrosis market position with 86% gross margins and 35% net income margin. Recent positive Phase 2b data for inaxaplin in kidney disease shows pipeline expansion potential. Revenue grew to $12.0B in 2025 with $3.95B net income, recovering from 2024's loss.
Analyst consensus remains strongly bullish with 84% buy ratings and $573.50 price target, representing 14% upside. Key risks include pipeline execution and competitive pressures. The stock offers growth potential through gene therapy expansion but faces volatility from clinical trial outcomes and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Harmony Gold Mining Co.
Harmony Gold Mining Co Ltd is a gold mining and exploration company having operations in South Africa and Papua New Guinea (PNG). Its projects include Bambanani, Joel, Masimong, Phakisa, Target 1, Tshepong, Unisel, Doornkop, and Kusasalethu. The group's segments are Tshepong Operations, Bambanani, Joel, Doornkop, Moab Khotsong, Hidden Valley, Target 1, Kusasalethu, Masimong, Unisel, and all other surface operations.
Read more on HMY →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
